Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 171

Drug Profile

AB 171

Alternative Names: AB171; LA 419

Latest Information Update: 20 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lacer
  • Developer ARCA biopharma Inc; Lacer
  • Class Furans; Heart failure therapies; Organic nitrates; Small molecules; Sugar alcohols; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chronic heart failure; Peripheral arterial disorders
  • No development reported Ischaemic heart disorders

Most Recent Events

  • 16 Nov 2017 ARCA biopharma receives patent covering AB 171 in Europe, including Denmark, France, Germany, Ireland, Italy, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom
  • 16 Nov 2017 ARCA biopharma has patents pending for AB 171 in USA and Canada
  • 16 Nov 2017 No development reported - Phase-II for Ischaemic heart disorders in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top